BOARD-ADVISORS-AG
3.11.2021 11:22:10 CET | Business Wire | Press release
LEA Partners GmbH (LEA), a private equity and venture capital investor based in Karlsruhe, Germany, today announced the acquisition of Base-Net Informatik AG (Base-Net), a Swiss software provider leading in the field of credit and mortgage management.
Board Advisors Deutschland AG acted as the exclusive M&A advisor to the shareholders of Base-Net. The team of Christoph Löslein, Urs Niederberger, Felix Brokatzky and Federico Arcelli was able to successfully complete the transaction in less than five months.
"I am extremely pleased that, through the efforts of Board Advisors, we were able to find a new majority shareholder that is equally beneficial to the customers and employees of Base-Net Informatik AG. Despite a complex transaction structure, the advisors of Board Advisors had the mandate under control at all times, were able to successfully complete the project in a record-breaking time and to the full satisfaction of the shareholders."
Stefan Hermann, Founder and Chairman of the Board of Base-Net Informatik AG
Base-Net, headquartered in Sursee in the canton of Lucerne, was founded in 1994. With its WinCredit software it is the leading Swiss software provider in the field of credit and mortgage management. Currently, over 400 banks, insurance companies, pension funds and financial intermediaries use the company's software. In addition, Base-Net develops and operates a state-of-the-art platform for credit and mortgage refinancing.
"The market for credit management software is continuously growing and is highly attractive for us. Therefore, we are very pleased to have gained Base-Net, another leading and long-established company, for us. With this, we are taking another step in building a leading financial services platform in the DACH region."
Philipp Hertel, Partner at LEA
About Base-Net
Base-Net is the leading Swiss software provider in the field of credit and mortgage management. In addition to its loan management software, its solutions for refinancing and exchanges with the Swiss Pfandbriefbank are among the standard solutions in the Swiss financial sector. Founded in 1994 and based in Sursee, the company now serves around 400 banks and insurance companies. For more information, please visit www.basenet.ch .
About LEA Partners
LEA Partners is an entrepreneurial equity partner supporting founders and management teams in different stages of development to grow and achieve a leading market position. Based in Karlsruhe, one of the largest technology clusters in Europe, LEA Partners has managed investments in numerous technology companies since 2002. Following the merger of PROCAD, keytech and ACATEC in May 2021 and that of TAIFUN, M-Soft and PinnCalc in October 2021, the establishment of a buy-and-build platform in the financial services sector, which already includes the b+m Group in addition to Base-Net Informatik AG, represents the next significant transaction for the LEA B2B Tech funds focused on software companies from the DACH region. For more information, please visit www.leapartners.de .
About Board Advisors
Board Advisors is a Management Consulting and M&A advisory firm founded in 2005 by Christoph Löslein and is today headquarted in Freiburg im Breisgau. Board Advisors currently has own operations in Berlin, Zurich, Sursee, Basel, Nice, Munich and Manchester and has a network of international cooperation partners.
Board Advisors has in-depth expertise in the health and technology sectors and has successfully completed numerous business development projects, buy- & sell-side transactions and fundraising mandates in recent years. For further information, please visit www.boardadvisors.de .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005562/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom